Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418
Serra V, Eichhorn PJA, GarcÃa-GarcÃa C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343
Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-94. doi:10.1038/nrd4051
Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014;39(1):220-9. doi:10.1038/npp.2013.181
Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-81. doi:10.1038/nature12873
Zhou P, Shaffer DR, Arias DAA, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014;506(7486):52-7. doi:10.1038/nature12988
Pop MS, Stransky N, Garvie CW, et al. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Mol Cancer Ther. 2014;13(6):1492-502. doi:10.1158/1535-7163.MCT-13-0689
Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216-20. doi:10.1126/science.1253533
de Boer S, Koszka K, Kiskinis E, Suzuki N, Davis-Dusenbery BN, Eggan K. Genetic validation of a therapeutic target in a mouse model of ALS. Sci Transl Med. 2014;6(248):248ra104. doi:10.1126/scitranslmed.3009351
Hyman S. Mental health: depression needs large human-genetics studies. Nature. 2014;515(7526):189-91. doi:10.1038/515189a